No Cohen Deposition At Martoma Insider-Trading Trial

Jan 9 2014 | 2:08pm ET

After two days, there is still no jury empanelled to hear the case against former SAC Capital Advisors portfolio manager Mathew Martoma. But when there is, it won't hear excerpts from SAC founder Steven Cohen's deposition last year.

Martoma's lawyers had sought to admit the deposition, arguing that it exonerated their client by showing that Cohen made trades in two pharmaceutical companies based on the recommendations of former SAC trader Wayne Holman, and not at Martoma's urging. But U.S. District Judge Paul Gardephe said yesterday that the deposition does no such thing, and is inadmissible anyway.

Gardephe called the deposition's characterization by Martoma's lawyers "not accurate," and in fact could incriminate their client.

"According to Cohen, Martoma played a significant role in his decision to buy Elan and Wyeth stock, and it was Martoma's discomfort with the Elan position on July 20, 2008, that was the impetus for selling the position," Gardephe wrote. Prosecutors have alleged that Martoma urged Cohen to sell the stocks after learning from a doctor overseeing a clinical drug trial that it was not going well.

"While the defendant asserts Cohen testified that Martoma had 'nothing to do with' Cohen's decision to sell the Wyeth position, Cohen actually said no such thing."

Not that the details matter: "Even if Cohen had testified that Martoma played no role in SAC's decision to sell its Wyeth and Elan stock and to sell short these securities—an assertion that is not supported by a review of Cohen's deposition transcript—this court would of course not be required to accept Cohen's account," the judge wrote.

Gardephe yesterday also expressed frustration with the jury-selection process, warning that it may force him to delay opening statements in the case by another day. Gardephe dismissed 26 potential jurors yesterday from an initial pool of 80. He will continue to question the remaining members of the pool today, but warned he may need to bring in a fresh jury pool to fill out the 12-member panel.

Prosecutors have called Martoma's alleged crimes the "most lucrative" insider-trading scam of all time, one which earned or saved SAC some $276 million. He faces up to 45 years if convicted—as all of the nearly 80 accused insider-traders to go to court in recent years have been.


In Depth

JOBS Act Propels Real-Estate Crowdfunding Platform

Oct 21 2014 | 2:57am ET

If D.J. Paul were a real estate development, he would be described as “multi-use...

Lifestyle

Strippers Accused Of Robbing Hedge-Fund Manager Face Jail

Oct 20 2014 | 9:20am ET

A group of alleged stripper-thieves—whose victims include a hedge-fund manager...

Guest Contributor

PAAMCO: European Equity Exposure - Challenging Year, But All is Not Lost

Oct 16 2014 | 4:12am ET

European equity hedge fund managers have had a tough time so far this year. The...

 

Videos

Editor's Note

    Must Attend Hedge Fund Charity Events For October

    Sep 30 2014 | 9:29am ET

    The crisp Autumnal days of October are upon us, and so are a few of the hedge fund industry’s favorite charitable events. If you have never been to Rocktoberfest, well, you are missing out. And for a quieter evening of sipping and socializing, stop by HFC’s Wine Soiree. Read more…

 

Futures Magazine

October 2014 Cover

Deeply flawed risk benchmark

Most traders agree that proper risk management is the key to successful trading. However, many traders depend on the deeply flawed measure of standard deviation as a benchmark of risk. Here we put it ...

The Alpha Pages

TAP July/August 2014 Cover

The Alpha Pages Interview: Senator Rand Paul

Senator Paul sat down in the debut series of the Alpha Pages Interview to discuss the broken tax code, regulation surrounding Bitcoin, and his plans for the 2016 Presidential election.